[D-CBP study: Evaluation of lung cancer management times].

Étude D-CBP : Évaluation des délais de prise en charge du cancer broncho- pulmonaire au sein du service de Pneumologie et d’Oncologie Thoracique du CHU de Caen.
Cancer broncho-pulmonaire Delay Diagnostic Délai Lung Cancer Medical pathway Parcours Traitement Treatment

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 26 02 2021
accepted: 28 07 2021
pubmed: 11 11 2021
medline: 18 11 2021
entrez: 10 11 2021
Statut: ppublish

Résumé

Lung cancer is the leading cause of cancer-related death. Delays may have an impact on patient survival. The objective of this study was to evaluate the diagnostic and therapeutic management times for patients admitted for lung cancer treatment in the Respiratory Department of CHU de Caen Normandie. This is a retrospective, single-center and observational study, conducted on all patients treated for lung cancer from June 2017 to January 2018 in our department of pneumology in the Caen Normandie CHU. The main median times were investigated were: Global Time (abnormal imaging-treatment), Diagnosis time (abnormal imaging-diagnosis) and Treatment Time (diagnosis-treatment). One hundred and twenty-seven (127) patients were included. Median global time was 55.5 days [31,25; 393], median diagnosis time was 22 days [13; 49], and median treatment time was 24.5 days [12,25; 45]. Our treatment times are consistent with those previously published. Areas for improvement are being developed in accordance with the 2014-2019 cancer plan, in particularly the creation in our institution of a specific care pathway for patients with lung cancer.

Identifiants

pubmed: 34756617
pii: S0761-8425(21)00339-9
doi: 10.1016/j.rmr.2021.09.002
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

fre

Sous-ensembles de citation

IM

Pagination

894-903

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Auteurs

S Deshayes (S)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

D Leite Ferreira (D)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

J Madelaine (J)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

Y Oulkhouir (Y)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

K Campbell (K)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

H Fouquet (H)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

S Teulier (S)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

R Magnier (R)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France.

M Heyndrickx (M)

Service de Chirurgie Thoracique, CHU de Caen, 14000 Caen, France.

D Lerouge (D)

Service de Radiothérapie, Centre de Lutte contre le Cancer François Baclesse, 14000 Caen, France.

E Bergot (E)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France.

A Justet (A)

Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France. Electronic address: justet-a@chu-caen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH